Insider Transactions in Q1 2022 at Ultragenyx Pharmaceutical Inc. (RARE)
Insider Transaction List (Q1 2022)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 11
2022
|
Thomas Richard Kassberg CBO & EVP |
SELL
Open market or private sale
|
Direct |
10,281
-4.32%
|
$688,827
$67.01 P/Share
|
|
Mar 07
2022
|
Karah Herdman Parschauer EVP and Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
5,140
-12.99%
|
$318,680
$62.95 P/Share
|
|
Mar 04
2022
|
Matthew K Fust |
BUY
Exercise of conversion of derivative security
|
Direct |
7,500
+24.43%
|
$300,000
$40.37 P/Share
|
|
Mar 03
2022
|
Mardi Dier CFO & Executive Vice President |
SELL
Open market or private sale
|
Direct |
420
-0.8%
|
$26,880
$64.55 P/Share
|
|
Mar 01
2022
|
Emil D Kakkis President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
52,041
+7.58%
|
-
|
|
Mar 01
2022
|
Emil D Kakkis President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
12,162
-2.05%
|
$814,854
$67.37 P/Share
|
|
Mar 01
2022
|
Camille L Bedrosian EVP and Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
14,000
+22.6%
|
-
|
|
Mar 01
2022
|
Camille L Bedrosian EVP and Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,821
-7.67%
|
$186,186
$66.62 P/Share
|
|
Mar 01
2022
|
Thomas Richard Kassberg CBO & EVP |
BUY
Grant, award, or other acquisition
|
Direct |
14,000
+5.79%
|
-
|
|
Mar 01
2022
|
Thomas Richard Kassberg CBO & EVP |
SELL
Open market or private sale
|
Direct |
2,374
-1.1%
|
$156,684
$66.62 P/Share
|
|
Mar 01
2022
|
Karah Herdman Parschauer EVP and Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
14,000
+26.13%
|
-
|
|
Mar 01
2022
|
Karah Herdman Parschauer EVP and Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
2,886
-10.18%
|
$190,476
$66.62 P/Share
|
|
Mar 01
2022
|
Dennis Karl Huang |
BUY
Grant, award, or other acquisition
|
Direct |
14,000
+21.53%
|
-
|
|
Mar 01
2022
|
Dennis Karl Huang |
SELL
Open market or private sale
|
Direct |
3,234
-8.06%
|
$213,444
$66.62 P/Share
|
|
Mar 01
2022
|
Theodore Alan Huizenga SVP, Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,710
+17.87%
|
-
|
|
Mar 01
2022
|
Theodore Alan Huizenga SVP, Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
843
-5.99%
|
$55,638
$66.62 P/Share
|
|
Mar 01
2022
|
John Richard Pinion |
BUY
Grant, award, or other acquisition
|
Direct |
14,000
+19.11%
|
-
|
|
Mar 01
2022
|
John Richard Pinion |
SELL
Open market or private sale
|
Direct |
4,498
-9.04%
|
$296,868
$66.62 P/Share
|
|
Mar 01
2022
|
Erik Harris EVP & Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
14,000
+27.82%
|
-
|
|
Mar 01
2022
|
Erik Harris EVP & Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
2,713
-10.84%
|
$179,058
$66.62 P/Share
|
|
Mar 01
2022
|
Mardi Dier CFO & Executive Vice President |
BUY
Grant, award, or other acquisition
|
Direct |
14,000
+21.14%
|
-
|
|
Mar 01
2022
|
Mardi Dier CFO & Executive Vice President |
SELL
Open market or private sale
|
Direct |
534
-1.38%
|
$35,244
$66.62 P/Share
|
|
Jan 30
2022
|
Camille L Bedrosian EVP and Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,657
-4.31%
|
$109,362
$66.3 P/Share
|